Background: It has previously been shown that increased levels of plasma tissue inhibitor of metalloproteinase 1 (TIMP-1) is associated with shorter survival for patients with colorectal cancer (CRC). Furthermore, plasma TIMP-1 levels have been found to be elevated in patients with early-stage CRC.
Objective: It was the aim of this study to develop a new dual monoclonal antibody (mAb) sandwich immunoassay for TIMP-1 in order to achieve better resolution of non-cancer and cancer plasma specimens.
Methods: Chemiluminescence immunoassay techniques were used to screen 240 combinations of TIMP-1 mAbs for their ability to interact with each other and to allow for further characterization of the sandwiching antibody pairs. Five mAb pair combinations were selected for assessment of their ability to resolve non-cancerous and cancerous plasma specimens by TIMP-1 measurement. Based on this testing, a final assay format was chosen for further validation. The results for the final assay were compared with measurements obtained in a TIMP-1 ELISA that had previously demonstrated the ability to resolve healthy blood donors and CRC specimens.
Results: The clinical results support that the new dual monoclonal immunoassay has statistical discrimination equivalent to the ELISA. Additionally, the immunoassay had a high reproducibility and specificity.
Conclusion: The clinical evaluation of five TIMP-1 immunoassays resulted in the development of a new immunoassay. The new TIMP-1 immunoassay showed superior analytical performance to our previously used ELISA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000096116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.
Cancer Immunol Immunother
January 2025
Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
The combined use of tocilizumab (TCZ) and immune checkpoint inhibitors (ICIs) in cancer treatment is gaining attention, but preclinical studies are lacking. Our study aims to investigate the synergistic anti-tumor effect of TCZ combined with ICIs and its role in treating immune-related adverse events (irAEs). The clinical significance of high interleukin-6 (IL-6) expression in tumor patients was analyzed from the Cancer Genome Atlas (TCGA) database.
View Article and Find Full Text PDFAssembly and performance of a cholera RDT prototype that detects both and associated bacteriophage as a proxy for pathogen detection.
J Clin Microbiol
December 2024
Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
Cholera rapid diagnostic tests (RDTs) are vulnerable to virulent bacteriophage predation. We hypothesized that an enhanced cholera RDT that detects the common virulent bacteriophage ICP1 might serve as a proxy for pathogen detection. We previously developed a monoclonal antibody (mAb) to the ICP1 major capsid protein.
View Article and Find Full Text PDFDual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study.
J Hematol Oncol
December 2024
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Co-inhibition of immune checkpoints lymphocyte-activation gene 3 (LAG-3) and PD-1 is believed to enhance cancer immunotherapy through synergistic effects. Herein, we evaluate the safety and efficacy of IBI110 (anti-LAG-3 antibody) with sintilimab (an anti-PD-1 antibody) in Chinese patients with advanced solid tumors.
Methods: In this open-label phase I study, phase Ia dose escalation of IBI110 monotherapy and phase Ib combination dose escalation of IBI110 plus sintilimab were conducted in patients with advanced solid tumors.
Preparation and Characterization of C-Reactive Protein Dual-Particle Latex-Enhanced Immunoturbidimetric Reagents.
BME Front
December 2024
Department of Laboratory Medicine and Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun 130021, China.
This study aims to couple C-reactive protein (CRP) antibodies onto latex spheres of 2 different sizes to enhance the accuracy and sensitivity of CRP detection. Furthermore, it seeks to establish a robust methodological framework crucial for advancing the development of latex-enhanced immunoturbidimetric detection reagents. CRP, an acute-phase protein, rapidly elevates in response to infections or tissue damage.
View Article and Find Full Text PDFEfficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.
Cancer Treat Rev
January 2025
SOLTI Cancer Research Group, Barcelona, Spain; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:
Article Synopsis
- Antibody-drug conjugates (ADCs) T-DXd and SG improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy in metastatic breast cancer (MBC) but have not been directly compared.
- A network meta-analysis revealed that T-DXd and SG had similar efficacy in hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low MBC, while T-DXd showed better results against standard chemotherapy.
- T-DXd demonstrated more favorable outcomes in HR+/HER2-low for both PFS and OS, but SG showed higher rates of specific side effects, including neutropenia and diarrhea, while T-DXd was associated with more serious adverse events like pneumonitis and cardiotoxicity
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!